Atrial fibrillation affects patients by increasing their riskof stroke and decreasing their quality of life. Unfortunately,even if restoration of sinus rhythm is possible, most patientsremain at risk for stroke and need continued protection withanticoagulation therapy.1,2 Patients with atrial fibrillationusually have shortness of breath, palpitations, and chest pain.An additional and less well appreciated symptom is fatigue,a nonspecific symptom in the elderly population that has a broaddifferential diagnosis. Since the risk of atrial fibrillationincreases with age and since the mean age of Western populationsis steadily rising, the well-described projected increase inthe . . . [Full Text of this Article]
Source Information
From the Lankenau Institute for Medical Research and Main Line Hospitals, Wynnewood, PA.
Related Letters:
Dronedarone in Atrial Fibrillation
Arlet J.-B., Chouchana L., Capron L., Fink A. H. Jr., Singh B. N., Hohnloser S. H., Ezekowitz M. D.
Extract |
Full Text |
PDF
N Engl J Med 2007;
357:2403-2405, Dec 6, 2007.
Correspondence
This article has been cited by other articles:
Arlet, J.-B., Chouchana, L., Capron, L., Fink, A. H. Jr., Singh, B. N., Hohnloser, S. H., Ezekowitz, M. D.
(2007). Dronedarone in atrial fibrillation.. NEJM
357: 2403-2404
[Full Text]
(2007). An Amiodarone Cousin Is Modestly Effective. JWatch Emergency Med.
2007: 4-4
[Full Text]
(2007). A New Treatment for Atrial Fibrillation on the Horizon?. Journal Watch Cardiology
2007: 1-1
[Full Text]
Previous
